Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Neurology

How Do I Find an IMNM Specialist or Referral Center?

At a Glance

People with immune-mediated necrotizing myopathy should seek a neurologist or neuromuscular specialist experienced in inflammatory muscle diseases, often at a referral center. Bring complete test records and seek urgent care for breathing, swallowing, or rapidly worsening weakness.

Finding a specialist for immune-mediated necrotizing myopathy (IMNM)—an exceptionally rare and severe autoimmune muscle disease—means looking for a physician who routinely manages inflammatory myopathies. General neurologists or rheumatologists may only see a few cases in their career, so the most effective care is often found at large neuromuscular or rheumatology referral centers [1][2]. These centers use a multidisciplinary approach, combining neurology, rheumatology, and specialized muscle pathology to accurately diagnose and manage the disease [1].

Urgent Symptoms: When Not to Wait

While finding a specialist is important, do not wait for a distant appointment if you experience life-threatening symptoms. Seek emergency or urgent medical care if you develop new or worsening shortness of breath, choking on liquids, an inability to swallow your saliva, a weak cough, or rapidly worsening muscle weakness that prevents you from standing or walking [3][4][5].

Identifying the Right Expertise

When building your care team, you need a doctor deeply familiar with the nuances of IMNM. Inflammatory myopathies can be difficult to classify and sometimes mimic other genetic or metabolic disorders, such as muscular dystrophy [6][7]. Therefore, finding a specialist who routinely coordinates care across different departments—such as interpreting autoantibody tests alongside electromyography (EMG, a test of nerve and muscle function) and muscle biopsies—is essential [1][2]. It is completely appropriate to ask a doctor directly how many IMNM patients they manage; specialists at national or regional referral centers often treat cohorts of these patients and are far more experienced in tracking disease progression [8][9].

Ensuring Accurate Diagnosis

Your specialist should be up-to-date on how this disease is classified. Specifically, you want to ensure they use the 2016 ENMC consensus diagnostic guidelines for IMNM [10]. The European Neuromuscular Centre (ENMC) framework relies on a complete clinical picture—combining symptoms like proximal muscle weakness, high creatine kinase (CK, a muscle enzyme) levels, and specific antibody testing to identify your subtype [10][11].

Under this framework, doctors look for three main categories:

  • Anti-HMGCR-positive IMNM: Often associated with prior statin (cholesterol medication) use, though it can occur in people who have never taken statins [12][13]. Note that stopping the statin alone does not treat the autoimmune disease; this must be actively managed by a doctor [14].
  • Anti-SRP-positive IMNM: Associated with more severe muscle weakness [12][11]. While IMNM generally has limited effects outside the muscles, this subtype can sometimes involve the heart or severe swallowing and breathing difficulties [15].
  • Seronegative IMNM: Where no specific autoantibodies are found on commercial panels. In these cases, a specialized muscle biopsy is often important to establish the diagnosis [16][17].

A doctor familiar with these guidelines understands that diagnosing IMNM relies on combining these tests. When a biopsy is used, a neuromuscular pathologist looks for prominent muscle fiber necrosis (cell death) and regeneration with very little inflammation, while also carefully ruling out toxic or inherited mimics [11][18][19].

Discussing Prompt, Individualized Treatment

Because IMNM can rapidly cause irreversible muscle damage and fatty replacement within the muscle tissue, prompt treatment is usually necessary [3][11]. A key indicator of a qualified specialist is their comfort level in prescribing and managing aggressive combination therapies when indicated, rather than relying solely on oral steroids [3][20].

Treatment should always be individualized based on your disease severity and antibody subtype:

  • Glucocorticoids & Steroid-Sparing Agents: High-dose steroids are commonly combined early with a steroid-sparing agent (medications like methotrexate used to reduce long-term steroid exposure and side effects) [21][20].
  • IVIG (Intravenous Immunoglobulin): This therapy may be added early for patients with substantial weakness, particularly those with the anti-HMGCR subtype, as observational studies suggest it can improve mobility [10][3][22].
  • Rituximab: This potent immunosuppressant is frequently considered for cases that relapse or do not respond to initial therapies. Observational data suggest it is also favored early by some experts for severe anti-SRP disease [3][23][24].

Ultimately, your specialist should outline clear treatment goals, alternatives, and an active monitoring plan. Monitoring must track not just your CK levels, but also your physical function (like rising from a chair), swallowing ability, and medication side effects—such as infection risk, elevated blood pressure, or bone density changes [21][25].

Preparing for Your Visit

To help your new specialist, bring a complete set of records:

  • Your full medication and statin history.
  • Trends of your CK levels over time.
  • Your complete autoantibody assay reports.
  • EMG or muscle MRI results.
  • Your muscle biopsy pathology report and, if possible, the actual biopsy slides for their pathologist to review.

Common questions in this guide

What type of doctor treats immune-mediated necrotizing myopathy?
IMNM is usually managed by a neurologist or neuromuscular specialist with experience in inflammatory muscle diseases, often working with rheumatology and a specialized muscle pathologist. Large academic neuromuscular or rheumatology referral centers may see more patients with this rare condition.
How can I tell whether an IMNM specialist has enough experience?
Ask how many IMNM patients the clinician currently manages and whether they routinely coordinate antibody testing, EMG, muscle biopsy, and treatment monitoring. Experience with the 2016 ENMC diagnostic guidelines and multidisciplinary care can be especially useful.
What records should I bring to an IMNM specialist appointment?
Bring your medication and statin history, CK results over time, complete antibody reports, EMG or muscle MRI results, and your muscle biopsy report. If possible, ask whether the pathology team can review the original biopsy slides.
When should I seek urgent care instead of waiting for an IMNM appointment?
Seek urgent or emergency care for new or worsening shortness of breath, choking on liquids, inability to swallow saliva, weak cough, or rapidly worsening weakness that prevents standing or walking. These symptoms can signal breathing or swallowing problems that need prompt assessment.
What treatments might an IMNM specialist consider?
Treatment may combine high-dose steroids with a steroid-sparing medicine, and intravenous immunoglobulin may be added for substantial weakness. Rituximab is often considered when disease relapses or does not respond, but the plan depends on severity, antibody subtype, and other health factors.
How is immune-mediated necrotizing myopathy diagnosed?
Doctors combine symptoms such as proximal weakness with CK levels, antibody testing, EMG, and sometimes muscle biopsy. A biopsy may show muscle fiber death and repair with little inflammation, while the team rules out toxic or inherited conditions.

Related questions

Can Muscle Strength Recover After a Delayed IMNM Diagnosis? Is Dark, Tea-Colored Urine an Emergency in IMNM? What to Do Does IMNM Cause Severe Muscle Pain? Evaluation and Care Does Statin-Induced IMNM Go Away After Stopping Statins? Do IMNM Antibody Levels Correlate With Disease Activity?
Show more
What Are the Early Warning Signs of an IMNM Relapse? Can Anti-SRP IMNM Cause Heart and Lung Complications? How to Read Your IMNM Muscle Biopsy Pathology Report How Does IMNM Affect Life Expectancy and Prognosis? Why Was I Initially Diagnosed With Muscular Dystrophy? Is Exercise Safe With IMNM? Weightlifting Guidance Is Immune-Mediated Necrotizing Myopathy Hereditary? How Is IVIG Used for Immune-Mediated Necrotizing Myopathy? What Are New and Experimental Treatments for IMNM? What Cancer Screening Is Needed for Seronegative IMNM? What Is Triple Therapy for IMNM? Medicines Explained How Does IMNM Cause Trouble Swallowing (Dysphagia)? What Are Typical CK Levels During an Active IMNM Flare? Why Is an MRI Used to Diagnose IMNM? What It Shows

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (25)
  1. 1

    Clinical features and diagnostic tools in idiopathic inflammatory myopathies.

    Tsamis KI, Boutsoras C, Kaltsonoudis E, et al.

    Critical reviews in clinical laboratory sciences 2022; (59(4)):219-240 doi:10.1080/10408363.2021.2000584.

    PMID: 34767470
  2. 2

    Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort.

    Yang H, Tian X, Zhang L, et al.

    BMC musculoskeletal disorders 2022; (23(1)):425 doi:10.1186/s12891-022-05372-z.

    PMID: 35524238
  3. 3

    Therapeutic management of immune-mediated necrotizing myositis.

    Weeding E, Tiniakou E

    Current treatment options in rheumatology 2021; (7(2)):150-160 doi:10.1007/s40674-021-00174-1.

    PMID: 34422547
  4. 4

    Statin-Associated Immune-Mediated Necrotizing Myopathy With Dual Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (Anti-HMGCR) and Anti-OJ Positivity: A Case Report of Fulminant Weakness and Respiratory Failure.

    Rahman MA, John D, Khan T, et al.

    Cureus 2025; (17(11)):e96123 doi:10.7759/cureus.96123.

    PMID: 41200259
  5. 5

    [Immune-mediated necrotizing myopathy: clinical and histopathological correlation].

    Marando JI, Ferrari MF, Cardiel F, et al.

    Medicina 2026; (86(4)):1055-1058.

    PMID: 42604521
  6. 6

    Pitfalls in the diagnosis of myositis.

    Chinoy H, Lilleker JB

    Best practice & research. Clinical rheumatology 2020; (34(1)):101486 doi:10.1016/j.berh.2020.101486.

    PMID: 32063440
  7. 7

    Clinicopathological features of anti-HMGCR and anti-SRP myopathies that do not satisfy the EULAR/ACR criteria of inflammatory myopathies.

    Komaki S, Kubota A, Kitamura A, et al.

    Rheumatology (Oxford, England) 2025; (64(8)):4580-4588 doi:10.1093/rheumatology/keaf183.

    PMID: 40178989
  8. 8

    Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy.

    Lim J, Rietveld A, De Bleecker JL, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2019; (6(1)):e513 doi:10.1212/NXI.0000000000000513.

    PMID: 30345336
  9. 9

    Clinicopathological and serological spectrum of idiopathic inflammatory myopathies: Experience from a neuromuscular referral center in Cyprus.

    Tsokkos T, Zamba-Papanicolaou E, Papacharalambous R, et al.

    Journal of neuromuscular diseases 2026; 22143602261476765 doi:10.1177/22143602261476765.

    PMID: 42611914
  10. 10

    Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.

    Sharf K, Do T, Ghetie D, et al.

    Arthritis care & research 2024; (76(11)):1584-1592 doi:10.1002/acr.25406.

    PMID: 39054727
  11. 11

    Immune-Mediated Necrotizing Myopathy.

    Pinal-Fernandez I, Casal-Dominguez M, Mammen AL

    Current rheumatology reports 2018; (20(4)):21 doi:10.1007/s11926-018-0732-6.

    PMID: 29582188
  12. 12

    Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.

    Watanabe Y, Uruha A, Suzuki S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2016; (87(10)):1038-44 doi:10.1136/jnnp-2016-313166.

    PMID: 27147697
  13. 13

    Spectrum of immune-mediated necrotizing myopathies and their treatments.

    Pinal-Fernandez I, Mammen AL

    Current opinion in rheumatology 2016; (28(6)):619-24 doi:10.1097/BOR.0000000000000335.

    PMID: 27607340
  14. 14

    Persistent HyperCKemia Beyond Post-Viral Myositis: A Case of Anti-HMGCR Immune-Mediated Necrotizing Myopathy.

    Xavier R, Silva S, Cunha R, et al.

    Cureus 2026; (18(9)):e116203 doi:10.7759/cureus.116203.

    PMID: 42877551
  15. 15

    Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts.

    Ma X, Bu BT

    Frontiers in immunology 2022; (13()):1019972 doi:10.3389/fimmu.2022.1019972.

    PMID: 36311711
  16. 16

    Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

    Allenbach Y, Benveniste O

    Current opinion in rheumatology 2018; (30(6)):655-663 doi:10.1097/BOR.0000000000000547.

    PMID: 30239349
  17. 17

    Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

    Allenbach Y, Benveniste O, Stenzel W, Boyer O

    Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

    PMID: 33093664
  18. 18

    Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

    Basharat P, Christopher-Stine L

    Current rheumatology reports 2015; (17(12)):72 doi:10.1007/s11926-015-0548-6.

    PMID: 26515574
  19. 19

    Necrotizing myopathies: an update.

    Quinn C, Salameh JS, Smith T, Souayah N

    Journal of clinical neuromuscular disease 2015; (16(3)):131-40 doi:10.1097/CND.0000000000000065.

    PMID: 25695918
  20. 20

    Anti-SRP-positive necrotising myopathy concurrent with breast malignancy.

    Dandasena T, Ingle V, Singhai A, Saigal S

    BMJ case reports 2023; (16(12)) doi:10.1136/bcr-2023-254702.

    PMID: 38081733
  21. 21

    Management of immune-mediated necrotizing myopathy.

    Suh J, Amato AA

    Muscle & nerve 2024; (70(2)):166-172 doi:10.1002/mus.28114.

    PMID: 38801022
  22. 22

    Effectiveness and Safety of IVIG for the Treatment of HMGCR Immune-Mediated Necrotizing Myopathy.

    Suh J, Amato AA

    Muscle & nerve 2025; (71(3)):392-397 doi:10.1002/mus.28333.

    PMID: 39731314
  23. 23

    Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.

    Xiong A, Yang G, Song Z, et al.

    Therapeutic advances in neurological disorders 2021; (14()):1756286421998918 doi:10.1177/1756286421998918.

    PMID: 33786066
  24. 24

    Clinical and persistent remission in anti-HMGCR immune-mediated necrotizing myopathy to a single cycle of rituximab - a case-based review.

    Silva SP, Eugénio G, Pinto M, Barcelos A

    ARP rheumatology 2024; (3(3)):231-236 doi:10.63032/ZVNO7794.

    PMID: 39243358
  25. 25

    Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies.

    Stano S, Cacciapaglia F, Coladonato L, et al.

    Reumatismo 2025; (77(3)) doi:10.4081/reumatismo.2025.1817.

    PMID: 40191951

This page is for educational purposes and does not replace medical advice. A qualified neuromuscular, neurology, or rheumatology specialist should interpret your IMNM symptoms, test results, and treatment options.